PROTEXT PHARMA APPOINTS CHIEF PHARMACIST TO OVERSEE CANNABIS MEDICINE OPERATIONS UPON ISSUANCE OF ANTICIPATED LICENSE IN SA
November 20 2017 - 11:24AM
InvestorsHub NewsWire
PROTEXT PHARMA APPOINTS CHIEF
PHARMACIST AS PART OF TEAM TO OVERSEE CANNABIS
MEDICINE OPERATIONS UPON ISSUANCE OF ANTICIPATED LICENSE IN
SOUTH AFRICA
FLORIDA, USA -- November 20, 2017 -- InvestorsHub
NewsWire -- Protext Pharma, Inc. (PINKSHEETS: TXTM)
("Protext" or "the Company"), a biotech company engaged in
the development of pharmaceutical botanical medicines that
are formulated with highly-bioavailable plant extracts, today announced that it has
appointed Mr. Tinus Lange to serve as a Chief Pharmacist for the
company’s South African subsidiary. Under regulations
approved earlier this month by the South Africa Medicine Control
Council (MCC), all applications for licenses to grow, process or
distribute medical cannabis must engage a qualified pharmacist to
oversee the operations. Mr. Lange’s business information,
pharmacy registration documents and security clearance, have been
forwarded to the MCC as the final part of the Company’s application
for a medical cannabis license.
Mr. Lange is a highly regarded pharmacist in the Mpumalanga
province of South Africa, having owned and operated his own
pharmacy since 1985. He graduated with the Pharmacology
degree in 1982 from North West University and co-developed the
first dispensing program ever used in South African
pharmacies. Pharmacology is a life-passion for Mr. Lange with
both his wife and daughter also being certified pharmacists
Roger Baylis-Duffield, Chief Executive Officer of Protext Pharma,
commented, “I am very pleased to have Mr. Lange’s join our
operations as Chief Pharmacist to oversee the development of our
cannabis medicines platform once our license is issued We
will be working closely together to develop cannabis-based
medicines that specifically address many of the disorders arising
from the human endocannabinoid system. Being able to deliver
a full-profile cannabis extract with up to 16 times the
bioavailability of current extracts, while also being
non-psychoactive, should give us a significant advantage in the
marketplace. As with Plandaí’s Phytofare® catechin
complex, similar claims will be made with the cannabinoid complex
through fact-based research and clinical trials. We intend to
conduct clinical trials to determine the effectiveness of the
Phytofare® cannabinoid extract in treating
inflammation. Increasing evidence suggests that the
endocannabinoid system, comprising cannabinoid receptors and their
endogenous ligands and metabolic enzymes, can regulate inflammation
in a wide variety of cells including osteoblasts and synovial
fibroblasts. An estimated 52.5 million adults in the United States
suffer from forms of arthritis, making it the single biggest cause
of disability. Two of the most common forms of arthritis,
osteoarthritis and rheumatoid arthritis are associated with pain
and joint damage due to loss of surface cartilage and bone within
synovial joints. Both conditions lead to a poor quality of life,
the inability to perform everyday tasks and, ultimately, permanent
joint damage.”
Mr. Lang added, “This is a very exciting time in South Africa as
just last Friday the MCC published a gazette officially changing
their controlled substance schedule, down grading cannabidiol, when
used for therapeutic purposes, from a schedule 6 drug to a schedule
4. I’m looking forward to working with the Company on
developing its medical cannabis extract that I believe ultimately
can help improve the quality of life of millions of people
worldwide.”
Once the anticipated license is issued,
the Company intends to commence cannabis operations at a
facility in the District of White River, South Africa, where plants will be grown, cloned and cultivated to
ensure a consistent chemical profile. The facility will
incorporate an on-site laboratory designed and engineered to
process live flower and plant material and, after separation and
recovery of the oil-phase as a separate income stream, the final
stage will be specific to the production of the Phytofare® complex
containing cannabinoids, cannabinoid acids, terpenes, limonene and
polyphenols. The resulting complex will be subjected to product
profiling, analysis and bioavailability in order to determine
efficacy and dosage. The Company will use its proprietary
processing and extraction technology to commence investigations and
produce a full-profile cannabis extract, one that contains both CBD
acids and the precursor acid form of THC (THC-A and THC-B) found in
live cannabis plant. The Company's investigations will be designed
to show that the our extraction process, which will use live leaf
and low temperatures to extract the phyto-chemicals, should leave
the acid forms of THC intact, resulting in a non-psychoactive
extract (schedule 4) with full medicinal potential and having the
heightened bioavailability of other Phytofare® extracts.
Investors are encouraged to follow Protext using:
YouTube: http://bit.ly/ProtextYouTube
Twitter: https://twitter.com/protxtm
Instagram: https://www.instagram.com/protextm/
CONTACT INFORMATION
Info@protextm.co
Contact: (435) 881-3611
About Protext Pharma, Inc.
Protext Pharma operates two wholly owned subsidiaries; Plandai
Biotechnology South Africa (Pty) Ltd. and Cannabis Biosciences,
Inc. The Company is engaged in the research, clinical testing
and commercialization of highly bioavailable botanical
products—all-natural ingredients formulated for pharmaceutical
applications and produced under pharma-grade conditions.
Please visit http://www.protextm.co for further
information.
About Plandai Biotechnology SA
Through its wholly owned subsidiary Plandai Biotechnology SA, the
Company has the exclusive worldwide license to develop Phytofare®
extracts from live plant materials including Phytofare® catechin
complex, a highly bioavailable, and clinically proven antioxidant
complex produced from live green tea leaves.
Phytofare® can deliver a therapeutic level of catechins, which
function as powerful antioxidants, to the system where they remain
active for over 24 hours.
About Cannabis Biosciences
The Company is actively pursuing government licensing that will
allow it to use its proprietary processing and extraction
technology to commence investigations and produce a full-profile
cannabis extract, one that contains both CBD and the precursor acid
form of THC (THC-A and THC-B) found in live cannabis plant. The
Company's investigations will be designed to show that the Cannabis
Biosciences extraction process, which will use live leaf and low
temperatures to extract the phyto-chemicals, should leave the acid
forms of THC intact, resulting in a non-psychoactive extract with
full medicinal potential and having the heightened bioavailability
of other Phytofare® extracts.
Safe Harbor Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance or guarantee that such expectations and assumptions
will prove to have been correct. Forward-looking statements are
generally identifiable by the use of words like "may," "will,"
"should," "could," "expect," "anticipate," "estimate," "believe,"
"intend," or "project" or the negative of these words or other
variations on these words or comparable terminology. The reader is
cautioned not to put undue reliance on these forward-looking
statements, as these statements are subject to numerous factors and
uncertainties, including but not limited to: adverse economic
conditions, competition, adverse federal, state and local
government regulation, international governmental regulation,
inadequate capital, inability to carry out research, development
and commercialization plans, loss or retirement of key executives
and other specific risks. To the extent that statements in this
press release are not strictly historical, including statements as
to revenue projections, business strategy, outlook, objectives,
future milestones, plans, intentions, goals, future financial
conditions, events conditioned on stockholder or other approval, or
otherwise as to future events, such statements are forward-looking,
and are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. The forward-looking
statements contained in this release are subject to certain risks
and uncertainties that could cause actual results to differ
materially from the statements made. The company disclaims any
obligation to update information contained in any forward-looking
statement. This press release shall not be deemed a general
solicitation.
ProText Mobility (PK) (USOTC:TXTM)
Historical Stock Chart
From Aug 2024 to Sep 2024
ProText Mobility (PK) (USOTC:TXTM)
Historical Stock Chart
From Sep 2023 to Sep 2024